The NHS is working with GRAIL to run the world’s first trial of a blood test as a potential screening tool for cancer in asymptomatic members of the public. The NHS-Galleri trial is currently nearing the end of its second of three years, with 140,000 participants providing annual blood samples to see whether the test results in more cancers being spotted at an earlier stage.

The test can spot signs of cancer due to tiny changes in DNA in the blood, and if initial results of this trial are positive, then the NHS will run a larger scale pilot in 2024 and 2025 using 1 million tests.

While this remains very much dependent on the initial NHS-Galleri trial data, planning for delivering that pilot is well underway. This session provides an opportunity for you to find out what it might mean for you, your organisation and your patients.